NASDAQ · MEDICINAL CHEMICALS & BOTANICAL PRODUCTS · SMALL CAP
Regencell Bioscience Holdings Ltd. RGC
7 fiscal years on record · USD · FY2024 reported · SEC filings only
$-3.6M
$-3.3M
Growth
—
Revenue, FY2024 · full 7-year series below
Compound annual growth
3 yrs
5 yrs
10 yrs
15 yrs
Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.
Profitability
—
ROE
FY2024 · ROE -54.8%
Each USD of equity lost 55 cents this year.
The 7-year record
7 fiscal years
Every figure from documents filed with the SEC · USD
EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.
row low → row highnegative
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|
| Revenue $B | · | · | · | · | · | · | · |
| Operating income $B | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 |
| EBITDA $B | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | · |
| Income tax $B | · | · | · | · | · | · | · |
| Net income $B | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 |
| Free cash flow $B | −0.0 | −0.0 | −0.0 | −0.0 | · | −0.0 | · |
| EPS, diluted $ | −0.72 | −0.87 | −1.19 | −0.58 | −0.13 | −0.08 | · |
| Dividend / sh $ | · | · | · | · | · | · | · |
| Payout % | · | · | · | · | · | · | · |
| ROE % | −54.8 | −42.5 | −40.4 | −114.0 | · | · | · |
| Shares out B | 0.49 | 0.49 | 0.01 | 0.01 | 0.01 | 0.01 | · |
Slide the table for earlier years · "·" marks a figure not available in our data for that year.
Provenance
Company facts, as filed
How we verify · 3 failures in 25 reconciliationsAUDITED
Reconciled in 4 of 19 fiscal years. 51 checks could not be computed.
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente3 failures
ActivityMedicinal Chemicals & Botanical Products
Listed onNASDAQ
Incorporated inoutside the United States — SEC code E9
Fiscal year endsnot stated in the filings
SEC categoryemerging growth company
Data on record since2018